Provided by Tiger Fintech (Singapore) Pte. Ltd.

Travere Therapeutics, Inc.

21.15
+0.39001.88%
Post-market: 21.150.00000.00%16:20 EDT
Volume:2.33M
Turnover:48.90M
Market Cap:1.88B
PE:-5.19
High:21.71
Open:21.09
Low:20.15
Close:20.76
Loading ...

Travere Therapeutics (TVTX) Receives a Buy from Guggenheim

TIPRANKS
·
04 Apr

Travere Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
01 Apr

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025

Business Wire
·
01 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital

Reuters
·
18 Mar

BUZZ-Travere rises on co's marketing application for kidney disease drug

Reuters
·
17 Mar

Travere Therapeutics Shares up 4.8% After Co Submits US Marketing Application to the FDA for Kidney Disease Treatment

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS

Reuters
·
17 Mar

Travere Therapeutics Inc: Plans to Submit Amendment to Rems Snda Currently Under Review for Modification of Liver Monitoring

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Inc: Continues to Expect a Rems Modification Pdufa Target Action Date of August 28

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Inc: FDA Notified Company That Rems Monitoring for Embryo-Fetal Toxicity Is No Longer Necessary

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Submits Snda to FDA for Approval of Filspari® (Sparsentan) for the Treatment of Fsgs

THOMSON REUTERS
·
17 Mar

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS

GlobeNewswire
·
17 Mar

Travere Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
27 Feb

Travere Therapeutics (TVTX) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
25 Feb

Travere Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire
·
25 Feb

Guggenheim Keeps Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
23 Feb

Travere Therapeutics price target raised to $30 from $24 at TD Cowen

TipRanks
·
22 Feb

Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
22 Feb

Travere Therapeutics (TVTX) Gets a Buy from Scotiabank

TIPRANKS
·
21 Feb

CORRECTED-U.S. RESEARCH ROUNDUP-Blue Owl Capital, Insulet, Unity Software

Reuters
·
21 Feb